Papakonstantinou E, Prasse A, Schacht V, Kapp A, Raap U
Department of Dermatology and Venereology, Hannover Medical School, Hannover, Germany.
Department of Pulmonology, Hannover Medical School, Hannover, Germany.
J Eur Acad Dermatol Venereol. 2016 Aug;30(8):1354-6. doi: 10.1111/jdv.13657. Epub 2016 Mar 23.
Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal pulmonary disease with an estimated 5-year survival of approximately 20%. Pirfenidone is a novel orally available antifibrotic agent that reduces disease progression and improves survival of patients with IPF. The most common adverse effects of pirfenidone include gastrointestinal symptoms, hepatic dysfunction or skin photosensitivity and rash. A 64-year-old male patient presented in our clinic with a strong generalized exfoliative erythema and intense itching accompanied by fatigue and mild fever after a mild sun exposure for 5 days during holidays in Turkey. The patient had been diagnosed with IPF 2 months ago and 1 month later he started a therapy with pirfenidone with good tolerability.
In this report, we noted a severe phototoxic reaction under treatment with pirfenidone which underlies the potential phototoxic effect of this drug besides the already reported photosensitivity.
Routine laboratory tests and a skin biopsy were performed.
Laboratory tests indicated increased markers of inflammation. The skin biopsy showed a perivascular lymphocytic inflammatory infiltrate, ballooning of keratinocytes with increased apoptosis. These findings were most consistent with a severe phototoxic reaction to pirfenidone which had been directly discontinued. The patient was started on oral methylprednisolone 100 mg/day which was gradually tapered off along with topical corticosteroids (mometasone furoate 0.1% cream) and oral antihistamines. This treatment led to a slow but complete resolution of the skin lesions within 20 days.
To our knowledge, this is the first reported case of a severe phototoxic reaction during treatment with pirfenidone. Our aim by presenting this case is to increase the awareness of clinicians for severe phototoxic effects of oral pirfenidone.
特发性肺纤维化(IPF)是一种进行性致命性肺部疾病,估计5年生存率约为20%。吡非尼酮是一种新型口服抗纤维化药物,可减缓疾病进展并提高IPF患者的生存率。吡非尼酮最常见的不良反应包括胃肠道症状、肝功能障碍或皮肤光敏感及皮疹。一名64岁男性患者在土耳其度假期间轻度日晒5天后,在我院就诊,表现为全身严重剥脱性红斑、剧烈瘙痒,伴有疲劳和低热。该患者2个月前被诊断为IPF,1个月后开始使用吡非尼酮治疗,耐受性良好。
在本报告中,我们注意到吡非尼酮治疗期间出现严重光毒性反应,这除了已报道的光敏感外,还揭示了该药物潜在的光毒性作用。
进行了常规实验室检查和皮肤活检。
实验室检查显示炎症指标升高。皮肤活检显示血管周围淋巴细胞炎性浸润,角质形成细胞气球样变伴凋亡增加。这些发现最符合对吡非尼酮的严重光毒性反应,遂直接停用该药。患者开始口服甲泼尼龙100mg/天,并逐渐减量,同时外用糖皮质激素(糠酸莫米松0.1%乳膏)和口服抗组胺药。该治疗使皮肤病变在20天内缓慢但完全消退。
据我们所知,这是首例报道的吡非尼酮治疗期间严重光毒性反应病例。我们报告此病例的目的是提高临床医生对口服吡非尼酮严重光毒性作用的认识。